The Beauty Health Company (SKIN) Q1 2025 earnings summary

Executive summary

• Q1 2025 net sales were $69.6 million, down 14.5% year-over-year, as delivery systems sales declined 43.5% but consumables grew 8.2%, now over 70% of revenue and supported by an active install base exceeding 35,000 units.

• Adjusted EBITDA improved to $7.3 million from $0.4 million year-over-year, reflecting cost reductions, margin gains, and disciplined execution of transformation strategy.

• Net loss widened to $10.1 million, mainly due to a prior-year gain on convertible note repurchase and lower sales.

• Strategic priorities include enhancing commercial execution, accelerating innovation, deepening provider partnerships, and new leadership driving operational improvements.

• Transition to a third-party distribution model in China is underway, with $4 million in related charges, and U.S. production consolidation has reduced tariff exposure.

Financial highlights

• Net sales for Q1 2025 were $69.6 million, down from $81.4 million in Q1 2024; gross margin improved to 69.8% from 59.4% year-over-year.

• Adjusted gross margin rose to 71.9% from 63.4% year-over-year; adjusted EBITDA margin improved to 10.4% from 0.4%.

• Consumables sales totaled $49.4 million, up 8.2% year-over-year, with strong growth in APAC (42.6%), EMEA (7.9%), and Americas (3.5%).

• Operating loss improved to $12 million from $17 million in the prior year; cash balance increased to $373 million.

• Delivery systems net sales fell 43.5% year-over-year to $20.2 million, impacted by macroeconomic challenges.

Outlook and guidance

• Full-year 2025 net sales expected between $270 million–$300 million, with adjusted EBITDA of $15 million–$25 million.

• Q2 2025 net sales projected at $71 million–$76 million, adjusted EBITDA of $2 million–$4 million.

• Guidance assumes continued macroeconomic pressure, especially in China, and includes $5 million in expected tariff costs.

• Capital expenditures for 2025 estimated at $10 million–$15 million; liquidity sufficient for at least 12 months.